Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Balancing efficacy and cancer risk of cyclophosphamide for patients with Wegener's granulomatosis

Nature Clinical Practice Rheumatology volume 4, pages 340–341 (2008)Cite this article

boxed-textFaurschou M et al. (2008) Malignancies in Wegener's granulomatosis: incidence and relation to cyclophosphamide therapy in a cohort of 293 patients. J Rheumatol 35: 100–105

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Talar-Williams C et al. (1996) Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124: 477–484

    Article  CAS  Google Scholar 

  2. Knight A et al. (2004) Urinary bladder cancer in Wegener's granulomatosis: risks and relation to cyclophosphamide. Ann Rheum Dis 63: 1307–1311

    Article  CAS  Google Scholar 

  3. De Groot K et al. (2005) Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum 52: 2461–2469

    Article  CAS  Google Scholar 

  4. Sneller MC et al. (1995) An analysis of forty-two Wegener's granulomatosis patients treated with methotrexate and prednisone. Arthritis Rheum 38: 608–613

    Article  CAS  Google Scholar 

  5. Jayne D et al. (2003) A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med 349: 36–44

    Article  CAS  Google Scholar 

  6. Langford CA et al. (2003) Use of a cyclophosphamide-induction methotrexate-maintenance regimen for the treatment of Wegener's granulomatosis: extended follow-up and rate of relapse. Am J Med 114: 463–469

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Jim Casey, Editorial Assistant, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Department of Rheumatic and Immunologic Diseases, ES Molloy is a staff member and CA Langford is the Director at the Center for Vasculitis Care and Research, Cleveland Clinic, OH, USA.,

    Eamonn S Molloy & Carol A Langford

Authors
  1. Eamonn S Molloy
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Carol A Langford
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carol A Langford.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Molloy, E., Langford, C. Balancing efficacy and cancer risk of cyclophosphamide for patients with Wegener's granulomatosis. Nat Rev Rheumatol 4, 340–341 (2008). https://doi.org/10.1038/ncprheum0822

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncprheum0822

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing